Pharmaceutical Bio's 150 million euro acquisition of Bayer Biopharmaceity's original liquid plant

recently, Pharmaceutical Biology and Bayer announced a deal. Under the agreement, Pharmaceuticals will acquire Bayer's biopharmaceous plant in Wuppertal, Germany, and plans to enter into a long-term sub-lease agreement and a transitional service contract for a total value of approximately EUR 150 million.The acquisition of the Biopharmaceus 19 Plant, MFG19) covers an area of 30,000 square meters, including 3 1000 liter irrigation lines and 6 2000 liter flow plus production lines, as well as independent downstream supporting facilities, which will further enhance the global supply capacity of Pharmaceuticals for new crown vaccines and other biological drugs. MFG19 will join forces with the Biologics Plant (DP7) in Leverkusen, Germany, to help Pharmaceuticals provide commercial production services. MFG19 and DP7 are expected to go into production in 2021, providing strong support for the European production supply chain for pharmaceutical products.The deal is subject to regulatory approval and is expected to close in the first half of 2021. (U.S.
)